Outsourcing

Jim Miller is president of PharmSource Information Services, Inc., and publisher of Bio/Pharmaceutical Outsourcing Report.

Articles

Changing demands in drug development lead to new service combinations and models.

R&D Mash-ups

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Relationship management is a limiting factor to growth in biomanufacturing outsourcing.

Project Managers Wanted

Rising labor costs in China may result in increased competition for higher value services.

Be Careful for What You Wish

Eli Lilly faces up to the new realities of the bio/pharmaceutical industry through outsourcing.

The Lilly Way

Restructuring in the biopharmaceutical industry is renewing a focus on resource optimization.

Waste Not, Want Not

CMOs' business model has all of the flaws of the captive model it is meant to replace.

Time for a Model Upgrade

Strategic rather than tactical considerations are driving biopharmaceutical outsourcing.

A Bio View of Outsourcing

Contract organizations waiting for the pipeline to come roaring back are kidding themselves.

Facing Reality

A new analysis highlights growth drivers and challenges for clinical supply-chain services.

Sizing Up the CDMO Market

Contract-service providers are expanding their offerings in this slow-growth environment.

Outsourcing Outlook